SSY Group gains NMPA approval for two new injection products

SSY Group Limited has received approval from China's National Medical Products Administration (NMPA) for the drug production and registration of Calcium Gluconate and Sodium Chloride Injection (100ml:1g/0.8g). This type 3 chemical drug passed consistency evaluation and is intended for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. This latest approval expands the group's calcium preparation series, complementing its Calcium Gluconate and Sodium Chloride Injection (100ml:2g/675mg) and Calcium Gluconate Injection (10ml:1g), approved on June 4, 2025, and July 18, 2025, respectively.

Additionally, the group secured NMPA approval for Morinidazole and Sodium Chloride Injection (100ml:0.5g/0.9g). Classified as a type 4 chemical drug, this product also passed the consistency evaluation. It is indicated for adults with gynecological pelvic inflammatory diseases and in combined surgical treatment for suppurative appendicitis and gangrenous appendicitis, caused by susceptible bacteria.

These approvals follow the company's August 19, 2025 announcement regarding the registration approval for SSY Group's Morinidazole bulk drug by the NMPA, allowing it to be used in preparations on the market. These developments highlight the group's continued focus on expanding its product pipeline within the Chinese pharmaceutical market.